Raman Sharma
Interventional Cardiology · New York, NYNPI 1134562358
Payments from drug & device makers
Across 422 payments — averaging $108.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$19K
- Cagent Vascular Inc$11K
- Abbott$8K
- Shockwave Medical, Inc$2K
- Cardiovascular Systems Inc.$999
- Bard Peripheral Vascular, Inc.$653
- plus $4K from 26 others
What the payments were for
- Consulting fees$12,96328%
- Speaking & faculty fees$1,0002%
- Travel & lodging$15,20833%
- Food & beverage$16,31636%
- Education$1600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 110 | $18,864 |
| Cagent Vascular Inc | 24 | $10,671 |
| Abbott | 79 | $8,403 |
| Shockwave Medical, Inc | 32 | $1,771 |
| Cardiovascular Systems Inc. | 33 | $999 |
| Bard Peripheral Vascular, Inc. | 19 | $653 |
| Boston Scientific | 14 | $503 |
| E.r. Squibb & Sons, L.L.C. | 21 | $474 |
| Amgen | 13 | $368 |
| Novartis | 15 | $326 |
| Terumo Medical Corporation | 9 | $309 |
| BD | 1 | $232 |
| Pfizer | 9 | $228 |
| Abiomed | 6 | $207 |
| Recor Medical Inc | 1 | $196 |
| Endologix LLC | 1 | $179 |
| Genentech USA, Inc. | 1 | $150 |
| Philips North America LLC | 2 | $147 |
| Johnson & Johnson | 6 | $133 |
| Chiesi USA, Inc. | 6 | $133 |
| Incyte Corporation | 1 | $125 |
| W. L. Gore & Associates, Inc. | 3 | $116 |
| Pharmacosmos Therapeutics Inc. | 1 | $101 |
| Tactile Systems Technology Inc | 3 | $94 |
| AstraZeneca | 4 | $83 |
| Cardiva Medical, Inc. | 2 | $41 |
| Reflow Medical Inc | 1 | $39 |
| AbbVie | 1 | $27 |
| Biotronik Inc. | 1 | $24 |
| Cordis US CORP. | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| Teleflex LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Serrantor$10,115
- SUPERA$3,323
- Omnilink Elite vascular stent system$2,763
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$1,003
- SYMPLICITY G3$810
- HawkOne$476
- Abre$297
- VENOVO$232
- PARADISE RENAL DENERVATION SYSTEM$196
- Torus Stent Graft System$179
- Supera peripheral stent system$177
- JETI$175
- IN.PACT Admiral$166
- Xience Sierra Coronary Stent System$160
- Activase$150
- IN.PACT AV$132
- (4067) Tack Endo Sys BTK$125
- JAKAFI$125
- Vascular Lithotripsy$117
- Monoferric$101
How this compares
$45,647 in reported general payments places this provider in the 70th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 96 | $72,288 |
| EliquisApixaban | 46 | $29,743 |
| Praluent PenAlirocumab | 33 | $15,079 |
| XareltoRivaroxaban | 16 | $14,462 |
| Gabapentin | 83 | $614 |
| Ranolazine ErRanolazine | 19 | $408 |
| Atorvastatin Calcium | 44 | $387 |
| Cephalexin | 220 | $337 |
| Rosuvastatin Calcium | 15 | $255 |
| ClopidogrelClopidogrel Bisulfate | 16 | $181 |
| Metoprolol Succinate | 22 | $126 |
| Amlodipine Besylate | 11 | $116 |
| Furosemide | 36 | $89 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 31 | $89 |
| Clindamycin Hcl | 27 | $55 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $228 | $29,74346 claims |
| Johnson & JohnsonXarelto | $133 | $14,46216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in New York
- Martin LeonNew York$13.5M
- Susheel KodaliNew York$6M
- Deepak BhattNew York$4.1M
- Samin SharmaNew York$3.7M
- Annapoorna KiniNew York$3.5M
- Sahil ParikhNew York$2.7M
- George DangasNew York$2.6M
- Prakash KrishnanNew York$2M
- Ajay KirtaneNew York$1.8M
- Shing-Chiu WongNew York$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.